English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

OBJECTIVEThe aim: To determine the features of atherosclerotic process, cardiovascular risk in patients with PsA.PATIENTS AND METHODSMaterials and methods: The study included 42 patients with PsA who did not have atherosclerotic CVD, diabetes, chronic kidney disease and other serious diseases, did not take statins, the comparingl group consisted of 20 patients with psoriasis (PS) and 20 practically healthy individuals who had no signs of rheumatic, infectious and other inflammatory diseases were screened.RESULTSResults: It was revealed that in patients with PsA, the severity of the atherosclerotic process is more compared with patients with PS (the RF profiles were the same). The highest levels of C-reactive protein, fibrinogen, uric acid, intima-media complex thickness, atherosclerotic plaque frequency were found in patients in the PsA group, which may indicate a pathogenetic association of additional RF with the development of a more common atherosclerotic process.CONCLUSIONConclusions: In the development of the atherosclerotic process in patients with PsA, the pro-traditional risk factors play an important role as the immune-inflammatory factors (CRP, IL-10) and additional risk factors (uric acid).

wiadomości lekarskie

FEATURES OF THE INTERCONNECTION OF TRADITIONAL RISK FACTORS AND IL-10 WITH THE ACTIVITY OF THE INFLAMMATORY PROCESS AND ATHEROSCLEROSIS DEVELOPMENT IN PATIENTS WITH PSORIATIC ARTHRITIS